[Bone fragility in type 1 diabetes and type 2 diabetes.]

Clinical calcium Pub Date : 2019-01-01 DOI:CliCa19015156
Tomoyasu Fukui, Yasuyoshi Takahashi
{"title":"[Bone fragility in type 1 diabetes and type 2 diabetes.]","authors":"Tomoyasu Fukui,&nbsp;Yasuyoshi Takahashi","doi":"CliCa19015156","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetes mellitus causes hyperglycemia due to resistance to insulin action in peripheral organs in addition to progressive loss of β-cell function, thus it is involved in the development and progression of diabetic microangiopathy(retinopathy, nephropathy, and neuropathy). In addition, abnormalities of bone metabolism is regarded as a chronic complication related to both type 1 diabetes and type 2 diabetes. Accumulating evidence suggests that type 1 diabetes patients had decreased bone mineral density(BMD)and the fracture risk in the femoral neck is markedly higher, when compared to non-diabetic patients. A lack of insulin level in the portal vein is associated with systemic deficiencies of Insulin-like growth factor-1(IGF-1), known as growth-promoting polypeptide essential for promoting growth and bone formation. Thus, loss of IGF-1 play a crucial role for the pathogenesis of reduced BMD in type 1 diabetes. In type 2 diabetes, despite high bone mineral density with obesity, several studies have shown that men and women with type 2 diabetes mellitus are at increased risk for bone fracture. In other words, unlike type 1 diabetes patients, an increase in the risk of fracture in type 2 diabetes is significantly related to compromised bone quality, the other factor of impaired bone strength.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 1","pages":"51-56"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical calcium","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/CliCa19015156","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetes mellitus causes hyperglycemia due to resistance to insulin action in peripheral organs in addition to progressive loss of β-cell function, thus it is involved in the development and progression of diabetic microangiopathy(retinopathy, nephropathy, and neuropathy). In addition, abnormalities of bone metabolism is regarded as a chronic complication related to both type 1 diabetes and type 2 diabetes. Accumulating evidence suggests that type 1 diabetes patients had decreased bone mineral density(BMD)and the fracture risk in the femoral neck is markedly higher, when compared to non-diabetic patients. A lack of insulin level in the portal vein is associated with systemic deficiencies of Insulin-like growth factor-1(IGF-1), known as growth-promoting polypeptide essential for promoting growth and bone formation. Thus, loss of IGF-1 play a crucial role for the pathogenesis of reduced BMD in type 1 diabetes. In type 2 diabetes, despite high bone mineral density with obesity, several studies have shown that men and women with type 2 diabetes mellitus are at increased risk for bone fracture. In other words, unlike type 1 diabetes patients, an increase in the risk of fracture in type 2 diabetes is significantly related to compromised bone quality, the other factor of impaired bone strength.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[1型糖尿病和2型糖尿病的骨质疏松。]
糖尿病由于外周器官对胰岛素作用的抵抗以及β细胞功能的进行性丧失而引起高血糖,参与了糖尿病微血管病变(视网膜病变、肾病、神经病变)的发生发展。此外,骨代谢异常被认为是与1型糖尿病和2型糖尿病相关的慢性并发症。越来越多的证据表明,与非糖尿病患者相比,1型糖尿病患者骨密度(BMD)降低,股骨颈骨折风险明显更高。门静脉胰岛素水平缺乏与胰岛素样生长因子-1(IGF-1)的全身性缺乏有关,IGF-1是促进生长和骨形成所必需的促生长多肽。因此,IGF-1的缺失在1型糖尿病骨密度降低的发病机制中起着至关重要的作用。在2型糖尿病中,尽管骨密度高且肥胖,但几项研究表明,2型糖尿病患者骨折的风险增加。换句话说,与1型糖尿病患者不同,2型糖尿病患者骨折风险的增加与骨质质量受损(骨质强度受损的另一个因素)显著相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Nomenclature on Cell Death, apoptosis and autophagic cell death.] [Perinatal bone and calcium metabolism in the patient complicated with renal dysfunction.] [Fracture management and current concepts related to pregnancy-associated osteoporosis.] [Pharmacological treatment for pregnancy and lactation associated osteoporosis.] [Prevention of osteoporosis during pregnancy and lactation period.]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1